Multiple clinical trials, ranging from Phase 1 safety evaluations to Phase 3 investigations, evaluate rimiducid (AP1903) as an inducible dimerizer switch for cell therapy control across active, non-recruiting, and planned stages. Sponsored by industry and academic entities such as Bellicum Pharmaceuticals, Poseida Therapeutics, and M.D. Anderson Cancer Center, these studies target graft-versus-host disease, pediatric brain tumors like diffuse intrinsic pontine glioma, and hematologic malignancies including acute myeloid leukemia, multiple myeloma, and lymphoma.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06066424 | RECRUITING | Solid Tumors |
M.D. Anderson Cancer Center |
2023-10-24 | PHASE1 |
| NCT07553390 | NOT_YET_RECRUITING | Breast Cancer |
M.D. Anderson Cancer Center |
2026-10-01 | PHASE1 |
| NCT06984341 | WITHDRAWN | Systemic Lupus Erythematosus |
Genentech, Inc. |
2026-06-30 | PHASE1 |
| NCT03741127 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Poseida Therapeutics, Inc. |
2018-10-29 | PHASE1 |
| NCT07164469 | NOT_YET_RECRUITING | Large B-cell Lymphoma; Hodgkin Lymphoma |
M.D. Anderson Cancer Center |
2026-12-28 | PHASE2 |
| NCT01494103 | ACTIVE_NOT_RECRUITING | Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Non Hodgkin Lymphoma; Hemophagocytic Lymphohistiocytosis; Familial Hemophagocytic Lymphohistiocytosis; Hemophagocytic Syndrome; Epstein Barr Virus Infection; X-linked Lymphoproliferative Disease |
Baylor College of Medicine |
2011-11 | PHASE1 |
| NCT06014762 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma (PMBCL); Transformed Follicular Lymphoma (tFL); Follicular Lymphoma Grade 3B; DLBCL; DLBCL - Diffuse Large B Cell Lymphoma; DLBCL Arising From Follicular Lymphoma; DLBCL, Diffused Large B Cell Lymphoma; DLBCL NOS |
Poseida Therapeutics, Inc. |
2024-04-16 | PHASE1 |
| NCT04960579 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Poseida Therapeutics, Inc. |
2022-05-05 | PHASE1 |
| NCT06358430 | ACTIVE_NOT_RECRUITING | Colorectal Cancer; Minimal Residual Disease |
M.D. Anderson Cancer Center |
2024-12-02 | PHASE1 |
| NCT07509008 | NOT_YET_RECRUITING | Gastric Cancer, Metastatic |
M.D. Anderson Cancer Center |
2026-09-01 | PHASE1; PHASE2 |
| NCT07598955 | RECRUITING | B2 Thymoma; Thymic Carcinoma |
Beijing Biotech |
2026-03-02 | PHASE1; PHASE2 |
| NCT02792114 | ACTIVE_NOT_RECRUITING | Breast Cancer; Metastatic HER2-negative Breast |
Memorial Sloan Kettering Cancer Center |
2016-06 | PHASE1 |
| NCT05239143 | ACTIVE_NOT_RECRUITING | Breast Cancer; Ovarian Cancer; Non Small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Renal Cell Carcinoma; Nasopharyngeal Cancer; Head and Neck Squamous Cell Carcinoma; Gastric Cancer |
Poseida Therapeutics, Inc. |
2022-02-15 | PHASE1 |
| NCT03016377 | ACTIVE_NOT_RECRUITING | Acute Lymphoblastic Leukemia; Immune System Diseases; Immunoproliferative Disorders |
UNC Lineberger Comprehensive Cancer Center |
2012-03-22 | PHASE1 |
| NCT03696784 | ACTIVE_NOT_RECRUITING | Lymphoma; Lymphoma, B-Cell; Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases |
UNC Lineberger Comprehensive Cancer Center |
2019-03-12 | PHASE1 |
| NCT04249947 | TERMINATED | Prostatic Neoplasms, Castration-Resistant; Neoplasms by Histologic Type; Neoplasms, Prostate; Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Neoplasms; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Prostatic Disease; Salivary Gland Cancer; Salivary Gland Tumor; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma; Mucoepidermoid Carcinoma; Acinic Cell Tumor |
Poseida Therapeutics, Inc. |
2020-02-28 | PHASE1 |
| NCT05298995 | Recruiting | Brain Tumor Pediatric|Medulloblastoma Childhood|Embryonal Tumor|High Grade Glioma|Diffuse Midline Glioma|Diffuse Intrinsic Pontine Glioma|Brain Tumor Adult |
Bambino Gesù Hospital and Research Institute |
2023-11-09 | Phase 1 |
| NCT02744287 | TERMINATED | Metastatic Castration-resistant Prostate Cancer; Metastatic Prostate Cancer |
Regeneron Pharmaceuticals |
2016-11-30 | PHASE1 |
| NCT03056339 | COMPLETED | B-Lymphoid Malignancies; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Non-hodgkin Lymphoma |
M.D. Anderson Cancer Center |
2017-06-21 | PHASE1; PHASE2 |
| NCT03459170 | ACTIVE_NOT_RECRUITING | Hematologic Malignancy |
Bellicum Pharmaceuticals |
2018-02-01 | PHASE1 |
| NCT03288493 | TERMINATED | Multiple Myeloma |
Poseida Therapeutics, Inc. |
2017-09-20 | PHASE1; PHASE2 |
| NCT02849886 | TERMINATED | Graft Versus Host Disease; Hematological Malignancies |
Centre Hospitalier Universitaire de Besancon |
2019-04-10 | PHASE1; PHASE2 |
| NCT03301168 | ACTIVE_NOT_RECRUITING | Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Primary Immune Deficiency Disorder; Osteopetrosis; Cytopenia; Hemoglobinopathy in Children; Anemia, Aplastic |
Bellicum Pharmaceuticals |
2014-04 | PHASE1; PHASE2 |
| NCT03807063 | WITHDRAWN | Acute Bilineal Leukemia; Myelodysplastic/Myeloproliferative Neoplasm; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Myeloproliferative Neoplasm; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome |
Fred Hutchinson Cancer Center |
2020-01-02 | PHASE1 |
| NCT03958656 | COMPLETED | Myeloma-Multiple; Myeloma, Plasma-Cell |
National Cancer Institute (NCI) |
2019-06-13 | PHASE1 |
| NCT03733249 | TERMINATED | Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Primary Immunodeficiency; Anemia, Aplastic; Hemoglobinopathies; Cytopenia; Fanconi Anemia; Diamond Blackfan Anemia; Thalassemia; Anemia, Sickle Cell |
Bellicum Pharmaceuticals |
2017-01 | PHASE1; PHASE2 |
| NCT02065869 | TERMINATED | Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin; Myelodysplastic Syndrome; Primary Immunodeficiency; Anemia, Aplastic; Osteopetrosis; Hemoglobinopathies; Cytopenia; Fanconi Anemia; Diamond Blackfan Anemia; Thalassemia; Anemia, Sickle Cell |
Bellicum Pharmaceuticals |
2014-04 | PHASE1; PHASE2 |
| NCT02477878 | ACTIVE_NOT_RECRUITING | Leukemia; Myelodysplastic Syndromes; Lymphoma; Multiple Myeloma; Hematologic Neoplasms |
Bellicum Pharmaceuticals |
2016-07 | PHASE1 |
| NCT03807063 | Withdrawn | Acute Bilineal Leukemia|Myelodysplastic/Myeloproliferative Neoplasm|Myelodysplastic/Myeloproliferative Neoplasm Unclassifiable|Myeloproliferative Neoplasm|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia BCR-ABL1 Positive|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome |
Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|Bellicum Pharmaceuticals |
2020-01-02 | Phase 1 |
| NCT01744223 | ACTIVE_NOT_RECRUITING | Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Lymphoma; Myelodysplastic Syndromes |
Bellicum Pharmaceuticals |
2013-03 | PHASE1; PHASE2 |
| NCT03699475 | TERMINATED | Acute Myeloid Leukemia; Myelodysplastic Syndromes |
Bellicum Pharmaceuticals |
2018-12-27 | PHASE2; PHASE3 |
| NCT02743611 | TERMINATED | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Uveal Melanoma |
Bellicum Pharmaceuticals |
2017-04-14 | PHASE1; PHASE2 |
| NCT02849886 | Unknown status | Graft Versus Host Disease|Hematological Malignancies |
Centre Hospitalier Universitaire de Besancon|Etablissement Français du Sang|Bellicum Pharmaceuticals |
2019-04-10 | Phase 1|Phase 2 |
| NCT02786485 | WITHDRAWN | Leukemia; Myelodysplastic Syndromes; Lymphomas; Multiple Myeloma; Other High-risk Hematological Malignancies |
Bellicum Pharmaceuticals |
2016-05 | PHASE1 |
| NCT03741127 | Active not recruiting | Multiple Myeloma |
Poseida Therapeutics Inc.|California Institute for Regenerative Medicine (CIRM) |
2018-10-29 | Phase 1 |
| NCT02487459 | WITHDRAWN | Hematologic Malignancies |
Bellicum Pharmaceuticals |
2016-07 | PHASE1 |
| NCT01875237 | TERMINATED | Leukemia; Myeloma; Myeloproliferative Diseases |
M.D. Anderson Cancer Center |
2013-12-27 | PHASE1; PHASE2 |
| NCT02107963 | COMPLETED | Sarcoma; Osteosarcoma; Neuroblastoma; Melanoma |
National Cancer Institute (NCI) |
2014-02-28 | PHASE1 |
| NCT02477878 | Active not recruiting | Leukemia|Myelodysplastic Syndromes|Lymphoma|Multiple Myeloma|Hematologic Neoplasms |
Bellicum Pharmaceuticals |
2016-07 | Phase 1 |
| NCT01823978 | COMPLETED | Castrate Resistent Prostate Cancer |
Bellicum Pharmaceuticals |
2013-04 | PHASE1 |
| NCT02231710 | TERMINATED | Primary Immune Deficiency Disorders; Hemophagocytic Lymphohistiocytosis; Inherited Bone Marrow Failure Syndrome; Hemoglobinopathies; Metabolic Disorders |
Bellicum Pharmaceuticals |
2015-02 | PHASE1 |
| NCT00868595 | COMPLETED | Castrate Resistant Prostate Cancer (CRPC) |
Bellicum Pharmaceuticals |
2009-04 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-05-15)
Check the
Rimiducid (AP1903)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.